Results indicate that fenofibrate may be an effective option for people with early diabetic retinopathy. Over 4 years, participants taking fenofibrate saw a 27% reduction in the progression of their eye disease compared to those taking the placebo.
Fenofibrate may likely reverse diabetes' effects and reduce inflammation in the retina, as well as improving dyslipidemia and hypertriglyceridemia. Fenofibrate increases levels of circulating apolipoprotein A-I, an independent protective factor for DR.
ApoM might be a useful biomarker for predicting the progression of diabetic nephropathy, and the ApoM/S1P-S1P1 axis might serve as a novel therapeutic target for preventing the development/progression of diabetic nephropathy.
Fenofibrate is available as Antara, Lipofen, TriCor, Triglide, Trilipix, and generic fenofibrate in the following dosage forms that are taken by mouth. 135 mg once daily, Delayed Release Capsule.
https://www.jwatch.org/na57657/2024/06/27/fenofibrate-slows-progression-diabetic-retinopathy
https://www.medscape.com/viewarticle/trial-fenofibrate-slows-diabetic-retinopathy-progression-2024a1000bm8
